Literature DB >> 15379997

Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma.

Frank Mauler1, Volker Hinz, Ervin Horváth, Joachim Schuhmacher, Heiko A Hofmann, Stephan Wirtz, Michael G Hahn, Klaus Urbahns.   

Abstract

Early deterioration and death after brain injury is often the result of oedema in the injured and peri-lesional tissue. So far, no pharmacotherapy is available that exhibits significant brain oedema-reducing efficacy in patients. We selected two low molecular weight compounds from different chemical classes, a triazole (1-[(2-chlorophenyl)diphenylmethyl]-1,2,3-triazole) and a cyclohexadiene (methyl 4-[4-chloro-3-(trifluoromethyl)phenyl]-6-methyl-3-oxo-1,4,7-tetrahydroisobenzofuran-5-carboxylate) to characterize their pharmacological properties on KCNN4 channels (intermediate/small conductance calcium-activated potassium channel, subfamily N, member 4) in vitro as well as in vivo. In vitro we replaced potassium by rubidium (Rb+) and determined Rb+ fluxes evoked by 10 micro m of the calcium ionophore A23187 on C6BU1 rat glioma cells. Compared with known KCNN4 blockers, such as clotrimazole (IC50=360 +/- 12 nm) and charybdotoxin (IC50=3.3 +/- 1.9 nm), the triazole and cyclohexadiene were considerably more potent than clotrimazole and displayed similar potencies (IC50=12.1 +/- 8.8 and 13.3 +/- 4.7 nm, respectively). In the rat acute subdural haematoma model, both the triazole and cyclohexadiene displayed reduction of brain water content (-26% at 0.3 mg/kg and -24% at 0.01 mg/kg) and reduction of the intracranial pressure (-46% at 0.1 mg/kg and -60% at 0.003 mg/kg) after 24 h when administered as a 4-h infusion immediately after brain injury. When infarct volumes were determined after 7 days, the triazole as well as the cyclohexadiene displayed strong neuroprotective efficacy (-52% infarct volume reduction at 1.2 mg/kg and -43% at 0.04 mg/kg, respectively). It is concluded that blockade of KCNN4 channels is a new pharmacological approach to attenuate acute brain damage caused by traumatic brain injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379997     DOI: 10.1111/j.1460-9568.2004.03615.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  27 in total

1.  The distribution of intermediate-conductance, calcium-activated, potassium (IK) channels in epithelial cells.

Authors:  Nichola Thompson-Vest; Yasutake Shimizu; Billie Hunne; John B Furness
Journal:  J Anat       Date:  2006-02       Impact factor: 2.610

2.  The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.

Authors:  Yi-Je Chen; Girija Raman; Silke Bodendiek; Martha E O'Donnell; Heike Wulff
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-13       Impact factor: 6.200

3.  Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity.

Authors:  Izumi Maezawa; Pavel I Zimin; Heike Wulff; Lee-Way Jin
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

Review 4.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

5.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

6.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

7.  Genetic deficit of KCa 3.1 channels protects against pulmonary circulatory collapse induced by TRPV4 channel activation.

Authors:  Christine Wandall-Frostholm; Thomas Dalsgaard; Vytis Bajoriūnas; Aida Oliván-Viguera; Veeruanjaneyulu Sadda; Lilliana Beck; Susie Mogensen; Edgaras Stankevicius; Ulf Simonsen; Ralf Köhler
Journal:  Br J Pharmacol       Date:  2015-07-24       Impact factor: 8.739

8.  NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.

Authors:  D Strøbæk; D T Brown; D P Jenkins; Y-J Chen; N Coleman; Y Ando; P Chiu; S Jørgensen; J Demnitz; H Wulff; P Christophersen
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 9.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

10.  KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.

Authors:  Mengni Yi; Panpan Yu; Qin Lu; Herbert M Geller; Zhihua Yu; Hongzhuan Chen
Journal:  Mol Cell Neurosci       Date:  2016-08-24       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.